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Objective: Initial treatment of juvenile idiopathic arthritis (JIA) is largely based on the extent of joint
involvement, disease severity and ILAR category. The licensing of biologic therapies for JIA has expanded
treatment options.
The aims of the study are (1) to describe treatment prescribing patterns in JIA over the ﬁrst 3 years
following ﬁrst presentation to paediatric rheumatology and (2) to determine whether patterns of
treatment have changed as biologics have become more widely available.
Methods: Children with at least 3 years of follow-up within the Childhood Arthritis Prospective Study
(CAPS) were included.
For analysis, children were placed into one of ﬁve groups according to their initial presentation to
paediatric rheumatology: oligoarthritis (oJIA), polyarthritis (pJIA), systemic (sJIA), enthesitis-related
arthritis (ERA) and psoriatic arthritis (PsA). Treatment patterns over 3 years were described.
Results: Of 1051 children, 58% received synthetic disease-modifying anti-rheumatic drugs (sDMARD) and
20% received biologics over the 3 years. Use of sDMARDs and biologics was higher in more severe disease
presentations (sJIA and pJIA); however, 35% and 10% who presented with oJIA were also treated with
sDMARDs and biologics, respectively. The number of children receiving sDMARD after 2006 was higher
(p ¼ 0.02); however, there was no difference in biologic prescribing before and after 2006 (p ¼ 0.4).
Conclusions: A high proportion of children presenting with JIA received sDMARDs plus/minus
biologics during 3 years of follow-up. This was most common for patients with severe JIA but was alsopport of Childhood Arthritis
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Juvenile idiopathic arthritis (JIA) is the most common chronic,
inﬂammatory rheumatic disease among children with a UK prev-
alence rate of approximately 1 in 1000 [1]. JIA is an umbrella term
for a heterogeneous group of conditions, classiﬁed according to the
International League of Associations for Rheumatology (ILAR), each
with its own distinctive characteristics [2]. Initial treatment is
largely based on the extent of joint involvement, disease severity
and category [3]. Typically intra-articular steroid injections are
given as ﬁrst-line treatment to patients presenting with oligoar-
thritis (deﬁned as four or less joints involved), while synthetic
disease-modifying anti-rheumatic drugs (sDMARDs) such as
methotrexate are indicated as ﬁrst-line treatment for systemic
and polyarticular presentations [3].
There remain a proportion of children who will not respond to
these initial therapies and further interventions will be required
[4]. For others, their category may evolve, such as an initial
oligoarticular presentation developing into a polyarticular course,
resulting in a stepup in therapy. The introduction of biological
agents in the last 15 years has offered further treatment options to
those with severe polyarticular or systemic disease who do not
respond adequately to initial therapy. However, the data regarding
the proportion of children in routine care who eventually require
biologics are generally lacking. Etanercept is the most commonly
prescribed biologic in JIA and has been shown to be efﬁcacious and
safe in a number of studies [5–8]. More recently, the evidenced
based choice of biologics for JIA has expanded to include other
anti-TNF therapies [e.g., adalimumab and inﬂiximab (off-label use
in Europe)] as well as alternative cytokine blockade for both
systemic and polyarticular JIA (e.g., the IL-6 inhibitor tocilizumab
and IL-1 blockade with anakinra) [9].
Treatment options for children with persistent oligoarthritis,
which does not respond to intra-articular steroid injections are
less clearly deﬁned as these children are not often included in
clinical trials, although many will be prescribed systemic therapies.
The extent to which this occurs is not well described, although a
recent Canadian study reported that patients presenting with
oligoarthritis have a 40% chance of receiving sDMARDs and a
6.6% chance of receiving a biologic over 5 years [10].
The primary aim of this analysis is to describe the patterns of
arthritis treatment prescribed among an inception cohort of
children over the ﬁrst 3 years following ﬁrst presentation to
paediatric rheumatology with JIA. The second aim is to look at
whether the patterns of treatment have changed in more recent
years as biologic therapies have become more widely available.Patients and methods
Patients
Children included in this study are participants in the Child-
hood Arthritis Prospective Study (CAPS), a prospective inception
cohort study of patients with JIA established in 2001 [11]. Children
o16 years with new onset arthritis in one or more joints lasting at
least 2 weeks are recruited from one of 7 UK rheumatology centres
within 6 months of ﬁrst presentation to paediatric rheumatology.The study was approved by the UK Northwest Multicentre
Research Ethics Committee. Written informed consent is obtained
from the parent(s)/guardian for all participant children and chil-
dren, if considered able, provide assent.
Data collection and follow-up
Following consent, data are captured from baseline (ﬁrst
presentation to paediatric rheumatology) by a clinical research
nurse using a standardised questionnaire, which captures infor-
mation including demographics and disease duration. Information
from clinical notes is also obtained including a physician-assigned
ILAR (where applicable), clinical markers of disease and a list of
current medication. JIA core outcome variables [12] are also
collected including active and limited joint counts, 10 cm visual
analogue scale (VAS) physician global assessment, 10 cm VAS
parent assessment of wellbeing, erythrocyte sedimentation rate
(ESR), the Childhood Health Assessment Questionnaire (CHAQ)
and a 10 cm visual analogue scale (VAS) pain score.
Patients are followed annually for 5 years, then at 7 and 10
years. At each follow-up visit, further data on current disease
activity, ILAR classiﬁcation, and changes to medications are
captured.
Statistical analysis
This analysis included all children with a physician diagnosis of
JIA recruited up to January 1, 2011 to allow all children the
opportunity to contribute at least 3 years of follow-up data by
January 1, 2014, the data cut-point.
Children were categorised into one of ﬁve disease presentations
according to the number of active joints at ﬁrst presentation to
paediatric rheumatology (study baseline) and their initial
physician-assigned ILAR category (within the ﬁrst 6 months fol-
lowing presentation): oligoarthritis (oJIA), polyarthritis (pJIA),
systemic (sJIA), enthesitis-related arthritis (ERA) and psoriatic
arthritis (PsA). Patients were classiﬁed into each category as
follows—oJIA: o5 active joints at ﬁrst presentation and an initial
ILAR category of persistent oligoarthritis or undifferentiated JIA
(uJIA) with o5 active joints, pJIA: Z5 active joints at ﬁrst
presentation and an initial ILAR category of rheumatoid factor
(RF) positive or negative polyarthritis, uJIA with Z5 active joints,
or extended oligoarthritis, SJIA: initial ILAR category of systemic
JIA, ERA: initial ILAR category of ERA and PsA: initial ILAR category
of PsA.
Children were excluded if they withdrew consent from the
study, had a missing ILAR category or joint count at baseline and 6
months, or were reclassiﬁed as not having JIA.
Treatment exposures over the ﬁrst 3 years following presenta-
tion to paediatric rheumatology were determined and categorised
into steroids [intra-articular, oral or intravenous (no intramuscular
steroids were recorded in this group)], sDMARDs and biologics.
The use of non-steroidal anti-inﬂammatory drugs (NSAIDs) could
not be reliably captured due to variable prescription and over the
counter use not well recorded in the dataset and therefore were
not included as a study outcome. For children who did not
complete 3 years of study, the reasons were noted and information
up to the point of last study follow-up was included. The time to
ﬁrst sDMARD and ﬁrst biologic among those who received these
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appointment to ﬁrst drug start date within the treatment category.
To explore any changes to prescribing since the inception of
CAPS, the cohort was divided into those recruited before and after
January 1, 2006, the midpoint in the study recruitment. For all
analyses, characteristics were compared across groups using non-
parametric descriptive statistics, namely chi-squared and Kruskal–
Wallis tests.
All analyses were performed using Stata, version 13 software
(StataCorp., College Station, TX).Results
To January 1, 2011, 1137 children had been recruited to CAPS.
We excluded 51 children with no ILAR assignment, nine with no
recorded joint counts, 23 who withdrew consent and three with a
diagnosis other than JIA, leaving 1051 children in this analysis (574
oJIA, 283 pJIA, 66 sJIA, 60 ERA and 68 PsA presentation) (Fig.).
Over the 3-year period, 137 had been lost to follow-up from the
study and 169 had been discharged from paediatric rheumatology,
for reasons including remission (40%), failing to attend appoint-
ments (26%) or transferring hospital (20%). The baseline character-
istics across the groups are shown in Table 1.
Treatment over the ﬁrst 3 years following initial paediatric
rheumatology appointment according to presenting
disease pattern
Overall
Of 1051 patients included in this analysis, 86% received steroids
in the ﬁrst 3 years following presentation to rheumatology. Over-
all, 58% received sDMARD therapy and 20% received a biologic
drug. The most commonly prescribed ﬁrst-line biologic was
etanercept (83%), then inﬂiximab (9%) and adalimumab (5%). Three
patients respectively were prescribed anakinra and tocilizumab
ﬁrst line with one prescribed canakinumab. There were 10%
(n ¼ 107) of patients for whom no use of steroids, sDMARDs or
biologics in the ﬁrst 3 years was recorded, including 55 who did
not complete 3 years in the study. Of these 55, 27% were dis-
charged well with 16% not attending clinic and 15% moving to
other clinics. The median time from presentation to rheumatologyn=1137 n=372
n=1051
n =51
n=9
n= 23
Fig. Study inclusion criteria.to a patient starting sDMARD was 2 months [interquartile range
(IQR): 0–8], with time to ﬁrst biologic 14 months (IQR: 8–23).Oligoarticular onset (oJIA)
A total of 574 patients presented with an oligoarticular pattern
of disease. In all, 83% were treated with steroids (either intra-
articular, oral or intravenous) over the ﬁrst 3 years following
presentation to paediatric rheumatology, and for 50% this was
their only treatment (Table 2).
A total of 35% of oJIA patients (n ¼ 199) received treatment
with sDMARDs, most commonly methotrexate (92%). Median time
from presenting to rheumatology to starting a ﬁrst sDMARD was
9 months (IQR: 3–17). Overall, 55 oJIA patients (10%) received
biologic therapy within 3 years, with a median time to ﬁrst
biologic of 23 months (IQR: 16–31). Etanercept was the most
commonly prescribed ﬁrst-line drug (67%), followed by inﬂiximab
(18%) and adalimumab (15%).
Patients with oJIA who received sDMARDs and biologics within
3 years had higher mean CHAQ, pain VAS and ESR scores at
presentation to rheumatology than those treated with steroids
alone (p o 0.05). Biologic treated patients were more likely to
have a history of uveitis (biologic 30%, sDMARD 16% and steroid
5%). They were also more likely to be re-assigned to a more severe
ILAR subtype within the ﬁrst 3 years, most commonly extended
oligioarthritis and polyarticular RF-negative JIA (Table 3). Oligoar-
ticular patients with a history of uveitis that were treated with
biologics were more commonly prescribed adalimumab and
inﬂiximab (n ¼ 13) as opposed to etanercept (n ¼ 4).Polyarticular onset (pJIA)
There were 283 patients with polyarticular disease at ﬁrst
presentation (71% RF-negative pJIA, 12% RF-positive pJIA, 8%
extended oligoarthritis and 9% undifferentiated JIA). In all, 94% of
these patients also received treatment with sDMARDs, mainly
methotrexate (98%). The median time from presentation to rheu-
matology to ﬁrst sDMARD was less than 1 month (Table 2).
A total of 56% of pJIA patients received sDMARDs without
receiving biologic therapy and 38% received biologics. The majority
were treated with etanercept initially (92%), with a median time to
ﬁrst biologic of 13 months (IQR: 7–20). Six patients were treated
with ﬁrst-line inﬂiximab, 2 tocilizumab and 1 starting
adalimumab.Systemic onset (sJIA)
Of the 66 patients presenting with systemic disease, 61 (93%)
received treatment with sDMARDs, 59% of whom had also received
steroids (Table 2). Over half of these patients had not received a
biologic within 3 years. Median time to ﬁrst sDMARD was 1 month
(IQR: 0–3). Biologic therapy was prescribed in 30%, with a median
time to ﬁrst biologic of 10 months (IQR: 5–21). Etanercept was the
most frequently prescribed ﬁrst biologic (65%), three patients
started anakinra, and one each started inﬂiximab, adalimumab,
tocilizumab and canakinumab.Enthesitis-related arthritis onset (ERA)
A total of 60 patients presented with ERA and over half were
treated with sDMARD therapy (Table 2). In all, 17% of patients were
not recorded as receiving any steroids, sDMARDs or biologics over
the ﬁrst 3 years and 27% were treated with steroids only. There
were 30% of patients that went on to receive biologic therapy; all
but one started etanercept as their ﬁrst treatment. The median
time to starting a ﬁrst biologic was 13 months (IQR: 10–19).
Table 1
Patient Characteristics at ﬁrst presentation to paediatric rheumatology
Characteristics Overall cohort oJIA pJIA sJIA ERA PsA p
N 1051 574 283 66 60 68
Age, median (IQR) 8 (3–12) 6 (3–10) 9 (4–12) 7 (4–11) 13 (11–14) 12 (7–13) 0.0001
Gender, % female 63 63 74 63 12 58 o0.0001
Disease duration (months), median (IQR) 5 (3–12) 5 (3–11) 6 (3–11) 2 (1–6) 8 (3–16) 8 (3–20) 0.0001
Active joint count, median (IQR) 2 (1–5) 1 (1–2) 8 (5–14) 3 (1–6) 2 (1–4) 3 (2–9) 0.0001
Limited joint count, median (IQR) 1 (1–3) 1 (1–2) 5 (2–10) 1 (0–5) 2 (1–4) 2 (1–5) 0.0001
ESR, median (IQR) 13 (6–32) 10 (5–25) 17 (8–39) 39 (10–84) 10 (5–25) 9 (5–25) 0.0001
CHAQ score, median (IQR) 0.5 (0–1.3) 0.3 (0–0.9) 0.8 (0.3–1.8) 0.6 (0.3–1.9) 0.1 (0–1.4) 0.8 (0.1–1.5) 0.0001
Pain VAS, median (IQR) 19 (2–49) 10 (1–39) 27 (5–56) 22 (9–64) 10 (0–33) 44 (7–64) 0.0001
Ever had uveitis, n (%) 82 (8) 55 (10) 19 (7) 0 5 (8) 3 (4) 0.071
Initial ILAR category, n (%)
Systemic JIA 66 (6) 0 0 66 (100) 0 0
Persistent oligoarthritis 531 (51) 531 (93) 0 0 0 0
Extended oligoarthritis 22 (2) 0 22 (8) 0 0 0
Polyarthritis RF ve 201 (19) 0 201 (71) 0 0 0
Polyarthritis RF þve 34 (3) 0 34 (12) 0 0 0
Enthesitis-related arthritis 60 (6) 0 0 0 60 (100) 0
Psoriatic arthritis 68 (6) 0 0 0 0 68 (100)
Undifferentiated arthritis 69 (7) 43 (7) 26 (9) 0 0 0
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Of 68 patients presented with PsA of whom 74% were treated
with sDMARD therapy, almost exclusively methotrexate (94%).
Median time from presentation to rheumatology to ﬁrst sDMARD
was less than 1 month. Overall, 16% of patients (n ¼ 11) received
biologic therapy, with 9 (82%) starting etanercept as their ﬁrst
treatment. The median time to ﬁrst biologic in those who received
this therapy was 14 months.
Treatment patterns by time
Patients presenting after January 1, 2006 were more often
prescribed steroids (80% before versus 90% after 2006, p o
0.001) and sDMARDs (54% versus 61%, p ¼ 0.02). Noted differences
between disease groups included a higher use of sDMARDs in
those presenting with ERA after January 1, 2006 (Table 4).
The median time to ﬁrst sDMARD therapy was similar [overall
before 2006: 3 months (IQR: 0–9); overall after 2006: 2 months
(IQR: 0–8); p ¼ 0.2]. There was a slight reduction in the time to
ﬁrst biologic, before 2006: 16 months (IQR: 9–28), after 2006: 14
months (IQR: 8–21), but did not reach statistical signiﬁcance (p ¼
0.2). A higher proportion of patients were prescribed etanercept as
a ﬁrst-line biologic before 2006 (91% versus 78%), small but similar
proportions presenting before/after January 1, 2006 received
inﬂiximab and anakinra, and the use of other biologics in those
presenting after January 1, 2006 expanded in line with drug
licensing.Table 2
Anti-rheumatic treatment patterns overall and within disease subgroups
Drug pattern
No steroida, sDMARD or biologic treatment, n (%)
Steroid ever, n (%)
Steroid only, n (%)
sDMARD ever, n (%)
sDMARD only (i.e., no biologic), n (%)
sDMARD þ steroid (no biologic treatment), n (%)
Median time from ﬁrst presentation to rheumatology to ﬁrst sDMARD [months (IQR)]
Biologic ever, n (%)
Median time from ﬁrst presentation to rheumatology to ﬁrst bio [months (IQR)]
a Steroids include intra-articular, oral, or intravenous treatment.Discussion
This large, prospective study of non-trial based-clinical care
describes the 3-year anti-rheumatic treatment patterns among
children with JIA following presentation to paediatric rheumatol-
ogy within one of ﬁve disease patterns, based on presenting active
joint count and ILAR category. Among all children, 58% received a
sDMARD and 20% received a biologic within this 3-year period,
none of whom were prescribed abatacept over the period of
observation. Rates of sDMARD use were highest in those present-
ing with polyarthritis and sJIA. However, 35% of those initially
presenting with oligoarthritis later went on to receive sDMARDs
and 10% received a biologic. These ﬁndings are not dissimilar from
those reported recently from a Canadian JIA inception cohort,
albeit over the ﬁrst 5 years of disease in this latter study [10].
Patients presenting with an oligoarticular pattern of disease are
typically treated initially with NSAIDs and intra-articular steroid
injections rather than sDMARD and/or biologic therapy (3). The
observation that many children with this presentation went on to
receive sDMARDs and biologics may have been inﬂuenced by
many factors. For some, an extension of their disease to extended
oligoarthritis or polyarticular PsA or uJIA would have prompted a
stepup in therapy. Our data also found that other factors related to
the disease such as uveitis was also higher in those prescribed
systemic therapy, although it was not known whether this was the
main factor in the decision to treat. Adalimumab and inﬂiximab
were prescribed more frequently in oJIA patients with a history ofOverall,
n ¼ 1051
Systemic,
n ¼ 66
Oligo,
n ¼ 574
Poly,
n ¼ 283
ERA,
n ¼ 60
PsA,
n ¼ 68
107 (10) 1 (2) 89 (15) 2 (1) 10 (17) 5 (7)
905 (86) 61 (92) 478 (83) 265 (94) 45 (70) 56 (82)
332 (32) 3 (5) 285 (50) 15 (5) 16 (27) 13 (19)
610 (58) 61 (93) 199 (35) 266 (94) 34 (56) 50 (74)
398 (38) 41 (62) 144 (25) 158 (56) 16 (27) 39 (57)
364 (35) 39 (59) 137 (24) 144 (51) 11 (18) 33 (49)
2 (0–8) 1 (0–3) 9 (3–17) 0.3 (0–3) 2 (0.2–4) 0.7 (0–6)
212 (20) 20 (30) 55 (10) 108 (38) 18 (30) 11 (16)
14 (8–23) 10 (5–21) 23 (16–31) 13 (7–20) 13 (10–19) 14 (5–22)
Table 3
Characteristics of oligoarthritis patients with differing treatment patterns
Oligoarthritis patients treated
with steroidsa only
Oligoarthritis patients treated with
sDMARDs only (no biologics)
Oligoarthritis patients ever
treated with biologics
N 285 144 55
Age, median (IQR) 7 (3–11) 5 (3–9) 6 (3–10)
Gender, % female 62 67 61
Disease duration (months), median (IQR) 5 (3–10) 5 (3–12) 4 (3–9)
Active joint count, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2)
Limited joint count, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2)
ESR, median (IQR)* 10 (4–20) 12 (6–34) 19 (6–40)
CHAQ score, median (IQR)* 0.1 (0–0.8) 0.5 (0–1.0) 0.8 (0–1.3)
Pain VAS, median (IQR)* 6 (0–29) 18 (2–42) 38 (7–62)
Median time from ﬁrst presentation to rheumatology
to ﬁrst DMARD (months (IQR))
10 (3–24) 8 (3–15)
Uveitis recorded during follow-up, n (%)* 13 (5) 23 (16) 17 (30)
Last recorded ILAR subtype over 3 years of
follow-up, n (%)*
Systemic JIA 0 1 (1) 0
Persistent oligoarthritis 230 (81) 89 (62) 18 (33)
Extended oligoarthritis 4 (1) 25 (17) 20 (36)
Polyarthritis RF –ve 4 (1) 9 (6) 5 (9)
Polyarthritis RF þve 1 (1) 1 (1) 2 (4)
Enthesitis-related arthritis 2 (1) 0 4 (7)
Psoriatic arthritis 4 (1) 4 (3) 1 (2)
Undifferentiated arthritis 9 (3) 1 (1) 1 (2)
Not recorded after ﬁrst presentation 31 (11) 14 (9) 4 (7)
n p o 0.05.
a Steroids include intra-articular, oral, or intravenous treatment.
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mab and inﬂiximab in treating uveitis, as well as less effective
treatment and in some cases a worsening of uveitis in patients
treated with etanercept [13]. There were, however, 60% sDMARD
and 30% biologic treated oligoarthritis patients respectively whoTable 4
Anti-rheumatic treatment patterns overall and within disease subgroups among childre
N Before January 1, 20
After January 1, 200
No steroid, sDMARD or biologic treatment, n (%) Before
After
p Value
Steroid ever, n (%) Before
After
p Value
sDMARD ever, n (%) Before
After
p Value
sDMARD only (no biologic treatment), n (%) Before
After
p Value
Median time from disease onset to ﬁrst sDMARD, months (IQR) Before
After
p Value
Biologic ever, n (%) Before
After
p Value
Median time from disease onset to ﬁrst biologic, months (IQR) Before
After
p Valuewere still classiﬁed at the 3-year follow-up as having persistent
oligoarthritis.
Despite a lack of clinical trial evidence for effectiveness in this
category, persistent oligoarticular disease unresponsive to steroids
may have prompted this decision to treat, particularly if persistentn recruited before and after January 1, 2006
Overall Systemic Oligo Poly ERA PsA
06 403 25 228 95 31 24
6 648 41 346 188 29 44
61 (15) 0 49 (21) 1 (1) 7 (23) 4 (17)
46 (7) 1 (2) 40 (12) 1 (0.5) 3 (10) 1 (2)
o0.001 0.4 0.001 0.6 0.2 0.03
323 (80) 25 (100) 176 (77) 83 (87) 23 (74) 16 (67)
582 (90) 36 (88) 302 (87) 182 (97) 22 (76) 40 (91)
o0.001 0.07 0.002 0.02 0.9 0.01
216 (54) 24 (96) 78 (34) 86 (91) 12 (39) 16 (67)
394 (61) 37 (90) 121 (35) 180 (96) 22 (76) 34 (77)
0.02 0.4 0.9 0.08 0.004 0.3
139 (34) 15 (60) 55 (24) 53 (56) 3 (10) 13 (54)
259 (40) 26 (63) 89 (50) 105 (56) 13 (45) 26 (59)
0.02 0.6 0.7 0.1 0.001 0.4
3 (0–9) 2 (0–3) 9 (4–18) 0.7 (0–5) 2 (0–11) 0.3 (0–1)
2 (0–8) 0.5 (0–2) 9 (3–17) 0.2 (0–2) 2 (1–3) 1 (0–11)
0.2 0.2 0.8 0.06 0.7 0.2
77 (19) 9 (36) 23 (10) 33 (35) 9 (29) 3 (13)
135 (21) 11 (27) 32 (9) 75 (40) 9 (31) 8 (18)
0.4 0.6 0.8 0.4 0.9 0.5
16 (9–28) 8 (2–24) 27 (13–34) 15 (8–26) 16 (10–35) 18 (10–26)
14 (8–22) 10 (7–16) 22 (18–27) 13 (7–20) 11 (10–19) 12 (4–18)
0.2 0.9 0.5 0.3 0.6 0.5
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dominant wrist and hip). Unfortunately, the granularity of data
available in CAPS prevented a further investigation into this
question.
Of patients with systemic arthritis, approximately one-third
went on to receive a biologic therapy in the ﬁrst 3 years. In the
context of more severe disease, it might be expected that more
children with sJIA would have been treated with biologics over this
time period. However, this could be explained by a good level of
disease control amongst this cohort with sDMARD alone. The
majority of children with sJIA across the duration of our study
were treated with TNFi as their ﬁrst choice biologic rather than IL-
1β and IL-6 inhibitors such as anakinra or tocilizumab [14].
However, for all but a minority of children, TNFi were the only
available biologic choice over the ﬁrst 3 years following presenta-
tion, with tocilizumab only licensed in 2011. A recent study from
the British paediatric biologic registers have shown that since
2010, a majority of UK children with sJIA who are starting a
biologic receive tocilizumab or anakinra as their ﬁrst-line biologic
therapy, although a majority do so after a trial of methotrexate
[15].
The strengths of the study relate to the size of the cohort, the
robust data collection methods employed and the prospective
study design to minimise recall bias. However, this study is not
without its limitations. It is an observational study capturing “real-
world” data recorded during routine care. As such, missing data on
both joint counts and ILAR categories were present, although a
majority of children had an initial active joint count recorded.
We also noted that many children were discharged or lost-to-
follow-up within the ﬁrst 3 years following recruitment, which
reﬂects the fact that many children will not remain under
rheumatology care in the UK if they achieve drug-free remission.
To reduce the potential of selection bias and maintain internal
validity, the analysis included all patients recruited within the
study period, including those who did not complete a full 3 years
within the study. The majority of children who were discharged
well had an oligoarticular presentation (77%). Therefore, excluding
these patients may have overestimated the proportions of children
requiring various therapies, particularly among the oligoarticular
presentation group. It is accepted that we may also have under-
estimated the use of sDMARDs or biologics in those children who
moved to a hospital, which was not participating in the CAPS
study, as follow-up could not be completed. The analysis also
consisted predominantly of patients diagnosed with JIA before the
licensing of new biologics including tocilizumab. This may affect
the generalisability of the data to a more modern JIA population,
although this can be seen more in the choice of biologic rather
than the decision to treat as all children presented within the
biologic era. We did not see an increase in the use of biologics in
the latter half of our study, only a wider range of biologics used.
To conclude, a high proportion of children presenting with JIA
received sDMARDs and/or biologics during 3 years of follow-up,
mainly in combination with or following initial steroid treatment.
A high percentage of children initially presenting with oligoar-
thritis, many of whom were still classiﬁed as having persistentoligoarthritis at their 3-year follow-up, were also treated with
biologic therapy. The use of biologics could in part be explained by
a history of uveitis in some but not all of these patients. The
effectiveness of biologic drugs in oligoarthritis is less well
described. While there has been some research suggesting good
methotrexate efﬁcacy in persistent oligoarticular JIA [16], more
research is needed to look at the effectiveness of both sDMARDs
and biologics in the oligoarticular category to ensure the appro-
priate use of advanced therapies in this population. It would also
be important to determine whether patient outcome is dependent
on a treatment plan that is speciﬁc to JIA category or extra-
articular manifestations versus level of active joints or disease
pattern, for example, the prescription of IL-1β and IL-6 inhibitors in
systemic JIA, which could serve to inﬂuence clinical decision
making in the future.
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